BlueWind Medical Brings Revi Implantable Tibial Neuromodulation Device to Patients in Shreveport, Louisiana
CustomersExpand
BlueWind Medical's Revi™ System Secures U.S. FDA De Novo Classification Grant for the Treatment of Urgency Incontinence
CustomersPartners
Clinical Study Results of the BlueWind System for Patients with Overactive Bladder Featured at the 2023 AUA Annual Meeting
Customers
BlueWind Medical to Present Positive Results from its Pivotal Trial in Patients with Overactive Bladder at the 2023 AUA Annual Meeting
Customers
BlueWind Medical Announces Key Milestone as AMA Issues Unique Category III CPT Code for Subfascial Placement of Tibial Neurostimulators
Customers
BlueWind Medical Appoints Dr. Liz Kwo to Board of Directors
Partners
BlueWind Medical Raises $64 Million to Fund Innovative Technology for Overactive Bladder (OAB) Treatment
Investment
BlueWind Medical appoints new CEO
Management Changes
BlueWind Medical Appoints New Executive Chairman
Management Changes
BlueWind Medical Announces Positive Long-Term Results of the BLUEWIND-RENOVA™ Implantable Tibial Nerve Neuromodulator
Customers
BlueWind Medical Appoints Dr. Roger R. Dmochowski, MD, MMHC, as Chief Medical Officer
Management Changes
BlueWind Medical Receives FDA Approval for Pivotal Trial Design of RENOVA iStim™ Implantable Tibial Nerve Neuromodulator for Overactive Bladder
Customers
BlueWind Medical Announces the Publication of Breakthrough Results for BLUEWIND-RENOVA™ Implantable Tibial Nerve Neuromodulator
Customers
BlueWind Medical Announces CE-Mark for the BlueWind VIVENDI™ Miniature Implanted Wireless Stimulator to Treat Peripheral Pain
Now there's needle-free Botox for your bladder
Customers
BlueWind Medical Announces CE-Mark for the First in the World Miniature Wireless Neurostimulator to Treat Overactive Bladder
Customers
BlueWind Medical Announces Successful Completion of Patients' Follow-Up for its Peripheral Neuropathic Pain (PNP) Study Toward a CE Mark
Customers